Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
50 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
LEO Pharma A/S - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'LEO Pharma A/S - Product Pipeline Review - 2014', provides an overview of the LEO Pharma A/S's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of LEO Pharma A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of LEO Pharma A/S including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of LEO Pharma A/S's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the LEO Pharma A/S's pipeline products Reasons to buy - Evaluate LEO Pharma A/S's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of LEO Pharma A/S in its therapy areas of focus - Identify new drug targets and therapeutic classes in the LEO Pharma A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of LEO Pharma A/S and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of LEO Pharma A/S - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of LEO Pharma A/S and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 LEO Pharma A/S Snapshot 6 LEO Pharma A/S Overview 6 Key Information 6 Key Facts 6 LEO Pharma A/S - Research and Development Overview 7 Key Therapeutic Areas 7 LEO Pharma A/S - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Combination Treatment Modalities 12 Pipeline Products - Partnered Products 13 Partnered Products/Combination Treatment Modalities 14 LEO Pharma A/S - Pipeline Products Glance 15 LEO Pharma A/S - Late Stage Pipeline Products 15 Phase III Products/Combination Treatment Modalities 15 LEO Pharma A/S - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 LEO Pharma A/S - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Discovery Products/Combination Treatment Modalities 19 LEO Pharma A/S - Drug Profiles 20 (calcipotriol + betamethasone dipropionate) 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 aprepitant 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 cromolyn sodium 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 ingenol mebutate 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 LEO-43204 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 LEO-27847 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 LEO-35299 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 LEO-39652 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 LP-0058 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 VBY-891 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 LP-0067 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Small Molecule to Inhibit MCHR1 for Obesity 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Ingenol Mebutate Analogs for Dermatology and Cancer 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 LEO Pharma A/S - Pipeline Analysis 34 LEO Pharma A/S - Pipeline Products by Target 34 LEO Pharma A/S - Pipeline Products by Route of Administration 35 LEO Pharma A/S - Pipeline Products by Molecule Type 36 LEO Pharma A/S - Pipeline Products by Mechanism of Action 37 LEO Pharma A/S - Recent Pipeline Updates 39 LEO Pharma A/S - Dormant Projects 42 LEO Pharma A/S - Discontinued Pipeline Products 43 Discontinued Pipeline Product Profiles 43 (calcipotriol + hydrocortisone) 43 HL-10 43 TD-1414 43 LEO Pharma A/S - Company Statement 44 LEO Pharma A/S - Locations And Subsidiaries 45 Head Office 45 Other Locations & Subsidiaries 45 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 50 Disclaimer 50
List of Tables LEO Pharma A/S, Key Information 6 LEO Pharma A/S, Key Facts 6 LEO Pharma A/S - Pipeline by Indication, 2014 9 LEO Pharma A/S - Pipeline by Stage of Development, 2014 10 LEO Pharma A/S - Monotherapy Products in Pipeline, 2014 11 LEO Pharma A/S - Combination Treatment Modalities in Pipeline, 2014 12 LEO Pharma A/S - Partnered Products in Pipeline, 2014 13 LEO Pharma A/S - Partnered Products/ Combination Treatment Modalities, 2014 14 LEO Pharma A/S - Phase III, 2014 15 LEO Pharma A/S - Phase II, 2014 16 LEO Pharma A/S - Phase I, 2014 17 LEO Pharma A/S - Preclinical, 2014 18 LEO Pharma A/S - Discovery, 2014 19 LEO Pharma A/S - Pipeline by Target, 2014 34 LEO Pharma A/S - Pipeline by Route of Administration, 2014 35 LEO Pharma A/S - Pipeline by Molecule Type, 2014 36 LEO Pharma A/S - Pipeline Products by Mechanism of Action, 2014 38 LEO Pharma A/S - Recent Pipeline Updates, 2014 39 LEO Pharma A/S - Dormant Developmental Projects,2014 42 LEO Pharma A/S - Discontinued Pipeline Products, 2014 43 LEO Pharma A/S, Other Locations 45 LEO Pharma A/S, Subsidiaries 47
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
